{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:39:41Z","timestamp":1793036381078,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s10147-026-03177-x","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:26:32Z","timestamp":1787660792000},"page":"2693-2701","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical value of prostate-specific antigen halving time as a predictor of response to first-line systemic treatment for synchronous metastatic castration-sensitive prostate cancer"],"prefix":"10.1007","volume":"31","author":[{"given":"Takanari","family":"Kambe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5321-6014","authenticated-orcid":false,"given":"Takayuki","family":"Sumiyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeru","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinari","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Nagumo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kawanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Oshiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoma","family":"Kurahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiko","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Makino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Kobori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusuke","family":"Akamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"3177_CR1","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.annonc.2023.02.009","volume":"34","author":"S Chowdhury","year":"2023","unstructured":"Chowdhury S, Bjartell A, Agarwal N et al (2023) Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer. Ann Oncol 34:477\u2013485. https:\/\/doi.org\/10.1016\/j.annonc.2023.02.009","journal-title":"Ann Oncol"},{"key":"3177_CR2","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.euo.2024.08.007","volume":"8","author":"M Wenzel","year":"2025","unstructured":"Wenzel M, Cano Garcia C, Humke C et al (2025) Prostate-specific antigen nadir and cancer-control outcomes in real-world apalutamide-treated metastatic hormone-sensitive prostate cancer patients: a single-center analysis. Eur Urol Oncol 8:364\u2013371. https:\/\/doi.org\/10.1016\/j.euo.2024.08.007","journal-title":"Eur Urol Oncol"},{"key":"3177_CR3","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1111\/bju.16449","volume":"134","author":"AS Merseburger","year":"2024","unstructured":"Merseburger AS, Agarwal N, Bjartell A et al (2024) Targeted investigational treatment analysis of novel anti-androgen (TITAN) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy. BJU Int 134:982\u2013991. https:\/\/doi.org\/10.1111\/bju.16449","journal-title":"BJU Int"},{"key":"3177_CR4","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/pros.24754","volume":"84","author":"M Wenzel","year":"2024","unstructured":"Wenzel M, Hoeh B, Hurst F et al (2024) Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real-world setting of metastatic hormone-sensitive prostate cancer patients. Prostate 84:1189\u20131197. https:\/\/doi.org\/10.1002\/pros.24754","journal-title":"Prostate"},{"key":"3177_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/pros.24797","volume":"85","author":"CH-M Wong","year":"2025","unstructured":"Wong CH-M, Ko IC-H, Leung DK-W et al (2025) Deep PSA response and extended time-to-nadir as robust predictors of survival in Asian patients with de novo metastatic hormone-sensitive prostate cancer receiving upfront intensified treatment. Prostate 85:30\u201339. https:\/\/doi.org\/10.1002\/pros.24797","journal-title":"Prostate"},{"key":"3177_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.prnil.2023.10.003","volume":"12","author":"A L\u00f3pez-Abad","year":"2024","unstructured":"L\u00f3pez-Abad A, Ram\u00edrez Backhaus M, Server G\u00f3mez G et al (2024) Real-world prostate-specific antigen reduction and survival outcomes of metastatic hormone-sensitive prostate cancer patients treated with apalutamide: an observational, retrospective, and multicentre study. Prostate Int 12:20\u201326. https:\/\/doi.org\/10.1016\/j.prnil.2023.10.003","journal-title":"Prostate Int"},{"key":"3177_CR7","doi-asserted-by":"publisher","first-page":"271.e9","DOI":"10.1016\/j.urolonc.2024.09.028","volume":"43","author":"F Urabe","year":"2025","unstructured":"Urabe F, Hatakeyama S, Yanagisawa T et al (2025) Clinical significance of PSA dynamics in castration-sensitive prostate cancer treated with ARSI doublet therapy: a multicenter study. Urol Oncol 43:271.e9-271.e18. https:\/\/doi.org\/10.1016\/j.urolonc.2024.09.028","journal-title":"Urol Oncol"},{"key":"3177_CR8","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1002\/cncr.24064","volume":"115","author":"TK Choueiri","year":"2009","unstructured":"Choueiri TK, Xie W, D\u2019Amico AV et al (2009) Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer 115:981\u2013987. https:\/\/doi.org\/10.1002\/cncr.24064","journal-title":"Cancer"},{"key":"3177_CR9","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1200\/JCO.2006.08.0572","volume":"25","author":"SJ Freedland","year":"2007","unstructured":"Freedland SJ, Humphreys EB, Mangold LA et al (2007) Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol 25:1765\u20131771. https:\/\/doi.org\/10.1200\/JCO.2006.08.0572","journal-title":"J Clin Oncol"},{"key":"3177_CR10","doi-asserted-by":"publisher","first-page":"E80","DOI":"10.1111\/bju.13856","volume":"120","author":"LE Howard","year":"2017","unstructured":"Howard LE, Moreira DM, De Hoedt A et al (2017) Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer. BJU Int 120:E80\u2013E86. https:\/\/doi.org\/10.1111\/bju.13856","journal-title":"BJU Int"},{"key":"3177_CR11","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/s0022-5347(17)53149-3","volume":"128","author":"PH Lange","year":"1982","unstructured":"Lange PH, Vogelzang NJ, Goldman A et al (1982) Marker half-life analysis as a prognostic tool in testicular cancer. J Urol 128:708\u2013711. https:\/\/doi.org\/10.1016\/s0022-5347(17)53149-3","journal-title":"J Urol"},{"key":"3177_CR12","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1002\/pros.20627","volume":"67","author":"E Banu","year":"2007","unstructured":"Banu E, Banu A, Medioni J et al (2007) Serum PSA half-life as a predictor of survival for hormone-refractory prostate cancer patients: modelization using a standardized set of response criteria. Prostate 67:1543\u20131549. https:\/\/doi.org\/10.1002\/pros.20627","journal-title":"Prostate"},{"key":"3177_CR13","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/aja.2008.36","volume":"11","author":"G-W Lin","year":"2009","unstructured":"Lin G-W, Yao X-D, Zhang S-L et al (2009) Prostate-specific antigen half-life: a new predictor of progression-free survival and overall survival in Chinese prostate cancer patients. Asian J Androl 11:443\u2013450. https:\/\/doi.org\/10.1038\/aja.2008.36","journal-title":"Asian J Androl"},{"key":"3177_CR14","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1007\/s10147-024-02577-1","volume":"29","author":"H Fujiwara","year":"2024","unstructured":"Fujiwara H, Kubota M, Hidaka Y et al (2024) A novel prognostic model of de novo metastatic hormone-sensitive prostate cancer to optimize treatment intensity. Int J Clin Oncol 29:1574\u20131585. https:\/\/doi.org\/10.1007\/s10147-024-02577-1","journal-title":"Int J Clin Oncol"},{"key":"3177_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","volume":"67","author":"D Bates","year":"2015","unstructured":"Bates D, M\u00e4chler M, Bolker B et al (2015) Fitting linear mixed-effects models using lme4. J Stat Softw 67:1\u201348. https:\/\/doi.org\/10.18637\/jss.v067.i01","journal-title":"J Stat Softw"},{"key":"3177_CR16","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM et al (2016) Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 34:1402\u20131418. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702","journal-title":"J Clin Oncol"},{"key":"3177_CR17","doi-asserted-by":"publisher","unstructured":"Soloway MS, Hardeman SW, Hickey D et al (1988) Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61:195\u2013202. https:\/\/doi.org\/10.1002\/1097-0142(19880101)61:1%3C195::AID-CNCR2820610133%3E3.0.CO;2-Y","DOI":"10.1002\/1097-0142(19880101)61:1%3C195::AID-CNCR2820610133%3E3.0.CO;2-Y"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03177-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03177-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03177-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:03:19Z","timestamp":1793034199000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03177-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["3177"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03177-x","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"19 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}